A single-center experience with abiraterone as treatment for metastatic castration-resistant prostate cancer

Abstract Background Continuous stimulation of the androgen receptor (AR) axis is a prerequisite for growth in castration-resistant prostate cancer (CRPC). Abiraterone acetate (AA) is a potent inhibitor of extracellular and intracellular androgen synthesis by inhibition of the CYP-17 enzyme system, w...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Urologic oncology 2016-07, Vol.34 (7), p.291.e1-291.e7
Hauptverfasser:	Thortzen, Anita, M.D, Thim, Stine, R.N, Røder, Martin Andreas, M.D., Ph.D, Brasso, Klaus, M.D., Ph.D
Format:	Artikel
Sprache:	eng
Schlagworte:	Abiraterone acetate Aged Aged, 80 and over Androgen Antagonists - therapeutic use Androstenes - therapeutic use Antineoplastic Agents - therapeutic use Efficacy Humans Male Metastatic castration-resistant prostate cancer Middle Aged Neoplasm Metastasis - drug therapy Prostatic Neoplasms, Castration-Resistant - drug therapy Prostatic Neoplasms, Castration-Resistant - pathology Retrospective Studies Routine practice Treatment Outcome Urology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!